Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver dis-
Introduction
Non-alcoholic fatty liver disease (NAFLD) is prevalent in approximately 20-30% of populations in developed countries, 1 with rates reported to be as high as 40-90% in subgroups with type 2 diabetes mellitus (T2DM) and obesity. 2, 3 Prevalence rates may be underestimated as the condition is asymptomatic and often goes undiagnosed and untreated until it has progressed. Insulin resistance (IR) is the underlying pathological mechanism and NAFLD is often referred to as the hepatic manifestation of metabolic syndrome. NAFLD occurs alongside hyperlipidaemia, abdominal obesity and/or hypertension. 4 NAFLD is an independent risk factor for cardiovascular disease (CVD), which is the leading cause of mortality in affected patients. 5, 6 Approximately 20% of NAFLD patients will develop the progressive form of the disease, non-alcoholic steatohepatitis (NASH). Individuals with NASH and liver fibrosis are at an increased risk of endstage liver disease, hepatocellular carcinoma (HCC) and all-cause mortality. [7] [8] [9] [10] Despite the high prevalence and risks associated with the disease, safe and effective evidence-based prevention and management strategies are lacking.
The diagnosis and staging of NAFLD is challenging as the gold standard for NASH-and NAFLD-related fibrosis is liver biopsy, 11 and less precise methods, such as serological/biochemistry scores, ultrasound and transient elastography (TE), are increasingly being used. 9, [11] [12] [13] Serological scoring systems and TE have an acceptable reliability at distinguishing cirrhosis from noncirrhosis. 11, [14] [15] [16] Ultrasound only identifies established cirrhosis and cannot be used to accurately stage disease or monitor progression. 13 Simple steatosis in NAFLD can be reversed with lifestyle modifications, preventing the progression to NASH and cirrhosis 7, 17, 18 ; however, many patients are not identified until they have advanced disease. High-risk groups with T2DM have a significant prevalence of liver injury as determined by TE. 19 Earlier detection and management 20 may prevent progression, with NAFLD projected to be the leading reason for liver transplant in 2020. 21, 22 The aim of this observational study is to determine the rates and characteristics of NAFLD patients referred to liver clinics in two metropolitan hospitals in Melbourne, Australia. We hypothesise that, in the absence of established screening practices and treatments, patients with NAFLD referred to and attending liver clinics for monitoring will represent a minority of the patient cohort and demonstrate progressed liver disease and established comorbidities.
Methods

Study participants and design
Liver clinic appointment lists were prospectively screened weekly at two metropolitan hospitals in Melbourne, Australia, to determine eligibility for a randomised controlled dietary intervention trial in NAFLD subjects. 23 Data were collected for 10 consecutive months at each respective site between October 2014 and June 2016. All patients aged ≥18 years were included, and the primary reason for clinic attendance was recorded. NAFLD diagnosis was based on the following: (i) sonographic diagnosis of fatty liver, defined as diffusely increased liver echogenicity (>right renal parenchyma) with vascular blurring, or biopsy-proven fatty liver disease; (ii) a negative history of alcohol consumption exceeding current Australian health guidelines 24 and (iii) exclusion of liver disease of other aetiologies, including drug-induced, autoimmune, viral hepatitis, cholestatic, metabolic and genetic liver disease. 
Results
There was a total of 2050 patients across two liver clinics during the 10-month period who were screened for this study regardless of clinic attendance (Fig. 1) . These clinics captured all NAFLD outpatients in the liver clinics, with the exception of those seen privately. Prevalence of medical diagnoses at the clinics is listed in Table 1 . There were 148 (7%) patients managed for NAFLD. The most common reason for clinic attendance was management of chronic hepatitis B (20%), alcoholic fatty liver disease (18%) and chronic hepatitis C (13%). Autoimmune hepatitis, haemochromatosis and primary biliary cholangitis represented 5%, 2% and 2% of clinic attendance, respectively, with other conditions comprising ≤1%. NAFLD was predominantly reported with ultrasound showing consistent radiological features (81%). Thirteen (9%) patients had NAFLD diagnosed by liver biopsy, with advanced liver fibrosis (F3) in three and cirrhosis (F4) in seven. A Brunt score was only available for nine (6%) patients, and scores ranged from 4 to 7 (Supporting Information Table S1 ). A large proportion of patients had TE Fibroscan (79%), and various liver biochemical measures were available in 78-97% of patients.
Group characteristics
The demographic, clinical and laboratory characteristics of patients with NAFLD are described in Table 2 . There were slightly more females (56%), and the median BMI was 30.7 AE 5.9 kg/m 2 , with 32% overweight and 40%
obese. The median LSM score was 6.5 (6.0) kPa; 18% of patients with NAFLD had an LSM score greater than 12 kPa and 7% greater than 20 kPa, suggestive of advanced fibrosis and cirrhosis respectively. The median alanine aminotransferase (ALT) level was elevated, significantly higher for males than females (P = 0.01). NAFLD patients were overall IR with a median HOMA score of 4.2 (3.2). The presence of comorbidities within the group is demonstrated in Table 2 . Of the NAFLD patients, 44% had T2DM, and an additional 10% had impaired glucose tolerance; 52% had hypertension, and 20% had a diagnosis of cardiovascular disease (CVD). Oral hypoglycaemic agents (OHA), statins and antihypertensive medications were reported in 35%, 30% and 37% of the cohort respectively.
LSM score
The cohort was further categorised according to liver disease severity based on an LSM cut-off score of < or ≥9.6 kPa, a value that has a positive predictive value of 72% for advanced fibrosis 27 ( Table 2) . Patients with NAFLD in the higher LSM group were older (mean age 59.9 AE 12.2 vs 52.9 AE 14.5 years, P = 0.006) and had significantly higher BMI (32.5 AE 6.4 and 29.6 AE 5.5 kg/m 2 , P = 0.02). Those with higher LSM scores also had higher median aspartate aminotransferase (AST) scores (40.0 AE 58.0 vs 25.0 AE 33.3 u/L, P = 0.0005). Median HOMA scores were significantly higher, indicating that the group with higher LSM scores were more IR (5.1 AE 2.6 vs 3.1 AE 3.2, P = 0.03). Total and low-density lipoprotein (LDL) cholesterol levels were lower in the group with higher LSM (4.6 AE 1.3 vs 5.2 AE 1.1 mmols/L, P = 0.01 and 1.1 AE 1.1 vs 3.1 AE 1.0 mmol/L, P = 0.031, respectively), and there was a higher use of statins in this group (25% vs 30%, P = 0.54). The group with higher LSM scores had greater rates of T2DM and hypertension: 33% vs 58%, P = 0.009 and 43% vs 65%, P = 0.023 respectively. Of note, there were 27 NAFLD patients with LSM scores >12 kPa, a score consistent with cirrhosis. 28 LSM scores significantly increased with increasing BMI (mean LSM in healthy weight 5.6 kPa AE 3.4, overweight 5.6 kPa AE 5.3, obese 6.6 kPa AE 9.4 and morbidly obese 9.9 kPa AE 9.1, P = 0.032). Significantly higher LSM scores were observed in those with a diagnosis of NAFLD and T2DM (32%) compared to NAFLD patients without T2DM (47%), median 8.5 (11.6) versus 5.9 (5.2) kPa, P = 0.011 respectively. Patients with NAFLD and hypertension (52%) had significantly higher LSM scores than normotensive NAFLD patients, median of 8.2 (8.8) kPa vs 5.7 (4.6) kPa, P = 0.011 respectively. 
Associations of variables with LSM scores
Correlational analysis was performed to assess the strength of associations between age, BMI and biochemical variables with LSM score. Table 3 displays the degree to which these variables correlate. The strongest correlations were reported for LSM score and HOMA (r = 0.49, P = 0.008) and LSM and AST (r = 0.42, P = 0.0005). Correlations between BMI (r = 0.27 P = 0.005), age (r = 0.28 P = 0.002), ALT (r = 0.20 P = 0.03) and LDL (r = −0.33 P = 0.002) showed weaker, albeit significant, associations with LSM. 
Regression analysis
A multiple regression analysis of LSM was conducted and demonstrated that age, BMI, AST, ALT, total cholesterol and LDL cholesterol remained significant. The model indicated that these variables explained 29.3% of the variance (R 2 = 0.293, F(6,81) = 5.59, P < 0.0005).
BMI, age and AST levels positively and significantly predict LSM score (β = 0.30, P = 0.003; β = 0.38, P = 0.0005; β = 0.23, P = 0.017 respectively). A separate univariate linear regression was conducted with HOMA as a predictor. This was not entered in the previous model as only 32 
Discussion
This observational study demonstrated that NAFLD constituted a minority of the liver clinic population, and NAFLD patients were predominantly obese with IR and had elevated liver enzymes and TE LSM scores consistent with mild fibrosis. Over half of the NAFLD patient group had T2DM, impaired glucose tolerance and hypertension, with 20% of the cohort diagnosed with CVD. Therefore, while NAFLD is highly prevalent in the community, this study demonstrated that it does not make up a large proportion of patients at established liver clinics. Low representation of this disease and management of the condition in the clinical setting is likely attributed to a number of factors, particularly in relation to its asymptomatic nature, the lack of routine screening practices of high-risk groups for NAFLD in the community, clinic fatigue in these patients and low rates of referrals to hepatology services by clinicians of those with suspected NAFLD. 29, 30 It is likely that the latter is related in part to an absence of pharmacological therapies for the disease.
Definitive diagnosis and staging are problematic as biopsy is expensive, invasive and not without risk, 12 explaining the low biopsy rate in this study (14%). Despite recommendations, liver biopsy is not a viable screening tool for at-risk patients, such as those with T2DM and NAFLD. 31 Routine biochemistry and ultrasound are of limited use in this group as they do not necessarily correlate with the severity of the liver disease, 32 and liver biochemistry elevation significantly underestimates the true prevalence of NAFLD and does not predict liver histology.
1,33 TE using Fibroscan is a rapid, noninvasive technique that is able to estimate the likelihood of significant liver fibrosis using LSM. It is particularly helpful in identifying the group with probable cirrhosis but is less reliable in lesser degrees of fibrosis. However, in NAFLD, it is less reliable than other liver diseases as success rates are lower in obese individuals when compared to non-obese counterparts. 28 In this study, individuals with higher LSM scores were obese, had raised liver enzymes, were IR and had significantly higher rates of HTN. The finding that elevated LSM was associated with decreased total cholesterol is consistent with previous literature. 34 NAFLD characteristically exists in a setting of altered metabolism, comprising abdominal obesity, IR, dysglycaemia and atherogenic dyslipidaemia, similar to CVD. 35, 36 This study highlights the elevated risk of progression to liver-related complications and CVD in patients with these features 11 Serological scoring systems may also be a noninvasive and rapid method to differentiate between NAFLD patients with and without advanced liver fibrosis. 14, 15 However, required data to calculate such scores were not available for this cohort.
This cross-sectional study shows that referral and management of patients with NAFLD in the tertiary setting is not optimal based on the known community prevalence of the condition. Australian data reflective of metropolitan areas for this age group (mean 55 years) reiterate this point, estimating that, in both males and females, prevalence is likely to be 25-30% of the population. 37, 38 Over half of the NAFLD patients in this study had T2DM or IGT. NAFLD poses an increasing risk of overall mortality compared to the general population (standardised mortality ratio 1.34), and T2DM poses an additional risk factor for death. 7, 39, 40 The presence of T2DM increases the CVD risk and has consistently been shown to be a key predictor of NASH and advanced fibrosis. [41] [42] [43] However, it may be impractical to propose the screening of all T2DM patients for significant liver disease. Similar to previous reports, our study showed a strong positive association with IR and LSM, consistent with other evidence of more severe liver disease in T2DM and IR. 39, [44] [45] [46] At present, there are no data available on the prevalence of NAFLD within individual Australian States and Territories. It is likely that, in rural areas and/or those with higher rates of indigenous populations, such as the Northern Territory and Western Australia, the prevalence of NAFLD may be even higher. Strategies to engage these patients in the community, with particular attention to people with T2DM and obesity, should be considered using an economic cost-benefit analysis to ascertain better investment of resources at the subclinical level of disease. Patient access to the tertiary setting is also important as it provides increased access to new and promising therapies as part of clinical trials. Multidisciplinary clinics for highrisk patients, such as those with T2DM, may be one such strategy to ensure the screening and management of NAFLD. This would encompass hepatologists and dietitians present during diabetes clinics.
The strengths of this cross-sectional study were that two major metropolitan hospitals were screened weekly for 10 months, capturing a cohort of over 2000 liver clinic patients, a generalisable subsample of the Melbourne clinical NAFLD patient group. However, biopsy data were infrequent, and diagnosis and staging relied on biochemistry and TE, with their previously mentioned limitations. 28 The main limitation of this study is that the overall sample size of patients with NAFLD was small, with missing laboratory values affecting some outcomes. The observational design also meant that there were unavailable data for the assessment of disease severity using serological scoring systems. For most patients, liver injury was staged using TE, which has limitations in obese patients and those with less advanced liver disease.
9,11
Conclusion
In conclusion, patients with NAFLD referred and managed in metropolitan liver clinics from two major hospitals constitute a minority of the liver disease population engaged in tertiary-level healthcare, despite high rates of NAFLD in Australia. Participants in this study with NAFLD had multiple components of the metabolic syndrome, including being overweight, IR and with almost 20% having TE levels suggestive of cirrhosis. Given the large proportion of the population with NAFLD and the small numbers captured in these clinical settings, screening of high-risk patients, such as those with diagnosed diabetes, cardiovascular risk factors or who are obese, is warranted to ensure earlier detection of the disease. As biopsy is invasive, surrogate markers, such as TE and HOMA scores, which are rapid and easily attainable, should be considered.
Introduction
The provision of domiciliary oxygen therapy to patients with chronic hypoxia is supported by two randomised trials performed over 30 years ago.
1,2 A mortality benefit was found with the use of supplemental oxygen ≥15 h per day in patients with severe hypoxaemia (PaO 2 25-53 mmHg) and stable chronic obstructive pulmonary disease (COPD). Importantly, a 2016 randomised control trial (RCT) demonstrated no benefit (neither mortality benefit nor hospitalisation minimisation) for domiciliary
